Current data from real-world settings indicate treatment initiation with lenalidomide and disease monitoring in patients with myelodysplastic syndrome with del(5q) (MDS-del[5q]) greatly vary, ...

Deletions of the long (q) arm of chromosome 5 [del(5q)]occur in patients with myelodysplastic syndromes (MDS) including, but not limited to, those who meet the WHO definition of the 5q− syndrome.

Lenalidomide has proven efficacy and safety and has been shown to reduce transfusion requirements and reverse cytogenetic abnormalities in lower-risk myelodysplastic syndromes (MDS). However, ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the European Commission (EC) has ...

Results from a retrospective study compared and explored biomarkers associated with outcomes in myelodysplastic syndrome (MDS) with plasma cell neoplasms. MDS is a group of heterogeneous clonal ...

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced positive top-line results from its IMerge Phase 3 clinical ...

Patients with lower risk myelodysplastic syndrome (MDS) — a type of cancer that starts in the bone marrow — may now have access to the experimental cancer drug, imetelstat, thanks to the Food and Drug ...